Cyfuse Biomedical K.K. Logo

Cyfuse Biomedical K.K.

4892 | T

Overview

Corporate Details

ISIN(s):
JP3311800001
LEI:
Country:
Japan
Address:
港区三田3−5−27 住友不動産三田ツインビル西館
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cyfuse Biomedical K.K. is a pioneering Japanese company specializing in innovative bioprinting technologies. Based in Tokyo with an additional office in Fukuoka, Cyfuse focuses on the development of advanced tissue engineering solutions, utilizing its proprietary 3D bioprinting platform. The company aims to revolutionize regenerative medicine by creating functional, living tissues for therapeutic applications, including drug testing and personalized medicine. With a commitment to research and development, Cyfuse Biomedical is at the forefront of transforming healthcare solutions and addressing critical challenges in tissue regeneration. Through its cutting-edge technology, Cyfuse is poised to make a significant impact on the future of medical treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 08:31
Regulatory News Service
確認書
Japanese 9.0 KB
2025-08-14 08:30
Interim Report
半期報告書-第16期(2025/01/01-2025/12/31)
Japanese 359.3 KB
2025-05-30 08:30
Registration Form
有価証券届出書(組込方式)
Japanese 924.1 KB
2025-03-26 03:03
Post-Annual General Meeting Information
臨時報告書
Japanese 21.4 KB
2025-03-26 03:02
Governance Information
内部統制報告書-第15期(2024/01/01-2024/12/31)
Japanese 22.7 KB
2025-03-26 03:01
Registration Form
有価証券報告書-第15期(2024/01/01-2024/12/31)
Japanese 2.2 MB
2025-03-26 03:01
Registration Form
確認書
Japanese 9.0 KB
2025-02-25 08:30
Audit Report / Information
臨時報告書
Japanese 20.6 KB
2024-08-14 08:33
Interim Report
確認書
Japanese 9.0 KB
2024-08-14 08:32
Interim Report
半期報告書-第15期(2024/01/01-2024/12/31)
Japanese 234.3 KB
2024-05-15 09:16
Report Publication Announcement
確認書
Japanese 9.0 KB
2024-05-15 09:15
Quarterly Report
四半期報告書-第15期第1四半期(2024/01/01-2024/03/31)
Japanese 196.4 KB
2024-04-17 10:10
Remuneration Information
臨時報告書
Japanese 43.2 KB
2024-03-27 08:18
Post-Annual General Meeting Information
臨時報告書
Japanese 23.2 KB
2024-03-27 08:17
Governance Information
内部統制報告書-第14期(2023/01/01-2023/12/31)
Japanese 22.8 KB

Automate Your Workflow. Get a real-time feed of all Cyfuse Biomedical K.K. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cyfuse Biomedical K.K.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cyfuse Biomedical K.K. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Bioengineering solutions to accelerate life sciences research, from gene synthesis to cell lines.
South Korea
355690
aTYR PHARMA INC Logo
Developing novel medicines for fibrosis and inflammation using tRNA synthetase biology.
United States of America
ATYR
Aura Biosciences, Inc. Logo
Developing virus-like therapies to selectively destroy solid tumors in ocular & urologic oncology.
United States of America
AURA
Aurinia Pharmaceuticals Inc. Logo
Biopharma developing therapies for autoimmune and kidney diseases like lupus nephritis.
United States of America
AUPH
AURORA CANNABIS INC Logo
A global producer and seller of medical and recreational cannabis and derivative products.
United States of America
ACB
Autolus Therapeutics plc Logo
Develops programmed CAR T-cell therapies for cancer and autoimmune diseases.
United States of America
AUTL
AVADEL PHARMACEUTICALS PLC Logo
Develops once-at-bedtime therapies for adults with narcolepsy using innovative drug delivery.
United States of America
AVDL
Avidity Biosciences, Inc. Logo
Pioneering targeted RNA therapies that treat the root cause of rare muscle diseases.
United States of America
RNA
Axsome Therapeutics, Inc. Logo
Biopharma company developing novel therapies for central nervous system (CNS) conditions.
United States of America
AXSM
AYTU BIOPHARMA, INC Logo
Specialty pharma advancing innovative medicines for CNS diseases like MDD and ADHD.
United States of America
AYTU

Talk to a Data Expert

Have a question? We'll get back to you promptly.